ConductScience.org, home

Library / Trial comparisons

Azithromycin vs Placebo: Proportion of Infants Developing Infantile Hypertrophic Pyloric Stenosis

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.00009180.00001620.00052wilsonClinicalTrials.gov
Risk in group 2000.000351wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.0000918-0.0002670.00052newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 2loga group has no participants with the outcomeClinicalTrials.gov
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zeroClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Azithromycin than on Placebo10,898from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Azithromycin
a single dose of Azithromycin will be administered to infants between their 8-27th days of life~Azithromycin: a single dose of Azithromycin will be administered to infants between their 8-27th days of life
110,898OG000ClinicalTrials.gov
Group 2Placeboa single dose of placebo will be administered to infants between their 8-27th days of life~Placebo: a single dose of Placebo will be administered to infants between their 8-27th days of life010,934OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleProportion of Infants Developing Infantile Hypertrophic Pyloric StenosisClinicalTrials.gov
DescriptionProportion of infants developing infantile hypertrophic pyloric stenosis between 2 to 8 weeks after treatmentClinicalTrials.gov
Time frame8 weeksClinicalTrials.gov
PopulationClinicalTrials.gov

Trial 8

FieldValueSource
TitleNeonates and Azithromycin, an Innovation in the Treatment of Children in Burkina FasoClinicalTrials.gov
NCT numberNCT03682653ClinicalTrials.gov
PhasesPHASE4ClinicalTrials.gov
ConditionsChildhood MortalityClinicalTrials.gov
InterventionsAzithromycin, PlaceboClinicalTrials.gov
Lead sponsorUniversity of California, San FranciscoClinicalTrials.gov
Results first posted2023-06-27ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT03682653?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.